GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - PRAXIS PRECISION MEDICINES INC

Explicit Guidance:

• Cash Runway: The company maintains $1.3 billion in cash, with runway extending into 2028, explicitly covering the upcoming launches of Ulexa and Relutrigine and further pipeline advancement.
• NDA Submission Timeline: An update regarding the expected submission date for the Elzab (Emerald) NDA for Retigine (SCN2A/8A) will be provided on Thursday (implying imminent submission, likely Q4 of the current fiscal year).
• Study Readouts: Data readouts for the Emerald study (Retigine) are expected to be disclosed "this week" or on Thursday, targeting a significant number of patients in the open-label phase.
• Launch Timing: Planning is in place to launch Ulexa "like today" if approved, with a target approval date around January; the company notes that scheduling classification (likely Schedule IV or V) could add a lag of approximately three months to the actual ship date but not the regulatory approval date.
• Romegene Power 3: Initiation of Power 3 studies is scheduled for next year (Q1 or early Q2), following the commencement of Power 2.

Business-Segment Outlook:

• Ulexa (Essential Tremor): Regulatory discussions with the FDA are "fairly advanced" and "very aligned" regarding labeling, specifically on titration and efficacy in subgroups. The company anticipates a broad label with no negative impacts on population coverage; the primary variable is the specific titration guidance required to manage discontinuation rates.
• Relutrigine (SCN2A/8A): Anticipates a "very clear positive" result for the Emerald study (SCN2A/8A) in a patient population 30 times larger than the previous indication, with a potential revenue impact described as "insanely interesting."
• Emerald (Elzab) Pipeline: BRAVE3 is expected to serve as the primary study for the NDA submission for the new indication, supported by a comprehensive Type B meeting where FDA alignment was secured on the analysis plan.
• Romegene (Power Trials): Power 2 is already "up and running"; Power 3 is being delayed until next year to optimize study design based on recent key opinion leader (KOL) advice, prioritizing data quality over speed.

Market and Competitive Outlook:

• Target Populations: The SCN2A/8A target population in the U.S. is estimated at 5,000 to 10,000 patients, representing a significantly unfulfilled medical need compared to the previous rare disease indications.
• Pricing Strategy: Management intends to move from "opinion to data" regarding pricing; they anticipate no price changes for approved drugs despite market dynamics, dismissing arguments about price increases as "stupid" given the value proposition.
• Competitive Differentiation: The company highlights a unique study design in Emerald where placebo was limited to four weeks, unlike previous studies, to capture data on long-term seizure reduction and patient stability in a fragile population.
• Supply Chain: While the company advocates for no scheduling (uncontrolled substance) for Ulexa, they prepare for a Schedule IV or V classification, which would primarily impact supply chain logistics rather than launch performance.

Macro / Industry Outlook:

• Regulatory Environment: The FDA is viewed as "understanding" the application's potential, particularly following the previous year's Breakthrough Therapy designation. However, the review cycle for Relutrigine is described as slightly "behind" Ulexa due to late-cycle information requests and leadership changes at the FDA (reviewer retirements).
• FDA Staffing: Management acknowledges that the "late review recently retired" and incoming reviewers may have caused minor delays in the Relutrigine cycle but does not anticipate a negative impact on the final outcome.
• Regulatory Risk: Management notes that while the outcome of Ulexa's NDA is "very high certainty," there is "slightly more uncertainty" for Relutrigine due to unresolved late-cycle questions, though both are expected to be approved.

Strategic Initiatives:

• Launch Preparation: The company is executing a "launch immediately" readiness plan for Ulexa contingent on the PDUFA date, including supply chain logistics for potential scheduling delays.
• Data Integrity Protocol: For the Emerald study, the company employs a rigorous QC process ("QC every entry, like every form, every field") to ensure high-quality readouts, accepting a longer timeline to avoid data errors.
• Pipeline Expansion: Continued advancement of Romegene with Power 2 active and Power 3 launching next year, aiming to create significant societal and investor value.
• Market Expansion: Preparing for the transition from the 5,000–10,000 patient pool (SCN2A/8A) to a broader potential market, potentially leveraging the 200,000 to 400,000 patient pool mentioned for the broader epilepsy market.

Risks and Headwinds to Outlook:

• Scheduling Uncertainty: The final decision on whether Ulexa is scheduled (controlled substance) remains pending; a Schedule IV/V designation could delay actual shipping by ~3 months post-approval.
• Labeling Specifics: While the label scope is broad, the specific titration guidance and management of discontinuation rates (which were high in previous studies) remain points of negotiation with the FDA, though the company believes current data supports a favorable outcome.
• Study Logistics: Delays in the Emerald study data readout are attributed to logistical documentation signing rather than clinical issues; however, the company warns that final dates depend on the completion of these administrative steps.
• Regulatory Review Variability: Relutrigine's review is slightly "behind" Ulexa's cycle, and while the outcome is expected to be positive, the exact PDUFA date is less visible than for Ulexa.

Management Tone on the Future:

• High Confidence: Marcio Marquez expresses "very high certainty" for Ulexa approval ("I can't be happier") and "very clear positive" expectations for the Emerald study.
• Defensive on Pricing: Management displays a firm stance against pricing debates, stating they will "not tolerate more debates" once data is presented.
• Operational Precision: Emphasis is placed on quality over speed (e.g., delaying Power 3, rigorous QC in Emerald), signaling a "quality-first" approach to regulatory success and data integrity.
• Forward-Looking Optimism: The tone suggests that while there are "open questions" for Relutrigine, the overall trajectory for the two launches and the pipeline is robust, with cash reserves supporting a "no impact" on financial health during the rollout.

Miscellaneous:

• Investor Day: A dedicated investor day is scheduled to take place in New York (or via webcast) to provide a comprehensive update on the company's trajectory and strategy.
• Study Comparison: The Emerald study population is described as distinct from the prior "Embold" study due to the specific genetics and fragility of the patients; direct quantitative comparison between studies is deemed "incredibly difficult" due to design differences (e.g., 4-week placebo limit).